CWM LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 137.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,970 shares of the biopharmaceutical company’s stock after buying an additional 48,672 shares during the period. CWM LLC’s holdings in Gilead Sciences were worth $5,943,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hall Laurie J Trustee raised its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the period. Cable Hill Partners LLC raised its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. raised its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the period. Finally, Penserra Capital Management LLC raised its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. 73.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.1716% during midday trading on Wednesday, hitting $75.5701. 4,528,360 shares of the stock were exchanged. The firm’s 50-day moving average is $70.60 and its 200-day moving average is $68.59. The stock has a market cap of $98.69 billion, a price-to-earnings ratio of 8.2079 and a beta of 1.21. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s revenue was down 8.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.08 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post $8.72 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Cwm LLC” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/02/cwm-llc-buys-48672-shares-of-gilead-sciences-inc-nasdaqgild-updated.html.
A number of equities analysts have recently commented on GILD shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, April 6th. Cowen and Company reiterated a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research report on Monday, April 17th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $73.87 price objective on the stock. in a research report on Tuesday, April 11th. Stifel Nicolaus restated a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Monday, April 24th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Twelve equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $80.31.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Francis Cogan sold 9,943 shares of the business’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the transaction, the director now owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. Insiders sold a total of 128,276 shares of company stock worth $9,190,610 over the last three months. Insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
